,address1,city,zip,country,phone,fax,website,industry,industryDisp,sector,sectorDisp,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,impliedSharesOutstanding,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,enterpriseToRevenue,enterpriseToEbitda,52WeekChange,SandP52WeekChange,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,uuid,messageBoardId,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,Wallstrasse 16,Berlin,10179,Germany,49 89 2153 9035,49 89 2153 9035 1,https://www.atai.life,Biotechnology,Biotechnology,Healthcare,Healthcare,"ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; GRX-917, a deuterated etifoxine for anxiety disorders; VLS-01 a N,N-Dimethyltryptamine for treatment resistant depression (TRD); DMX-1002, an oral formulation of ibogaine, a cholinergic, glutamatergic and monoaminergic receptor modulator that is a naturally occurring psychedelic product isolated from a West African shrub for the treatment of opioid use disorders (OUD); and EMP-01, an oral formulation of an MDMA derivative being developed for the treatment of post-traumatic stress disorder. The company's other clinical programs comprise PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; and KUR-101, a formulation of deuterated mitragynine for the treatment of OUD. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.",133,"{'maxAge': 1, 'name': 'Mr. Christian  Angermayer', 'age': 44, 'title': 'Founder & Chairman of the Supervisory Board', 'yearBorn': 1978, 'fiscalYear': 2022, 'totalPay': 70000, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.45,1.47,1.44,1.485,1.45,1.47,1.44,1.485,0.0,0.826614,-1.5934066,637940,637940,934611,511050,511050,1.44,1.49,1400,2900,240714512,1.14,3.9,884.9798,1.7788,1.919475,0.0,0.0,USD,35315192,0.0,133273210,166010000,4124529,4089623,1690761600,1693440000,0.0248,0.09632,0.30329,7.1,0.0325,166010000,1.28,1.1328126,1672444800,1703980800,1688083200,-145076000,-0.95,-0.91,129.835,-0.257,-0.6081081,0.14113986,NGM,EQUITY,ATAI,ATAI,ATAI Life Sciences N.V.,Atai Life Sciences N.V.,1624023000,America/New_York,EDT,8699f3bf-7398-34d0-b0ba-129948e2583d,finmb_710359021,-14400000,1.45,21.0,5.1,11.73,11.0,1.8,buy,9,227492000,1.37,-137632000,19005000,12.789,13.543,272000,8.813,0.002,-0.28601,-0.56173,233000,-56181624,-102275000,0.012,1.0,0.0,-506.8566,USD,
1,Wallstrasse 16,Berlin,10179,Germany,49 89 2153 9035,49 89 2153 9035 1,https://www.atai.life,Biotechnology,Biotechnology,Healthcare,Healthcare,"ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; GRX-917, a deuterated etifoxine for anxiety disorders; VLS-01 a N,N-Dimethyltryptamine for treatment resistant depression (TRD); DMX-1002, an oral formulation of ibogaine, a cholinergic, glutamatergic and monoaminergic receptor modulator that is a naturally occurring psychedelic product isolated from a West African shrub for the treatment of opioid use disorders (OUD); and EMP-01, an oral formulation of an MDMA derivative being developed for the treatment of post-traumatic stress disorder. The company's other clinical programs comprise PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; and KUR-101, a formulation of deuterated mitragynine for the treatment of OUD. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.",133,"{'maxAge': 1, 'name': 'Mr. Florian  Brand', 'age': 35, 'title': 'Co-founder & CEO', 'yearBorn': 1987, 'fiscalYear': 2022, 'totalPay': 835442, 'exercisedValue': 0, 'unexercisedValue': 9709600}",1672444800,86400,4,1.45,1.47,1.44,1.485,1.45,1.47,1.44,1.485,0.0,0.826614,-1.5934066,637940,637940,934611,511050,511050,1.44,1.49,1400,2900,240714512,1.14,3.9,884.9798,1.7788,1.919475,0.0,0.0,USD,35315192,0.0,133273210,166010000,4124529,4089623,1690761600,1693440000,0.0248,0.09632,0.30329,7.1,0.0325,166010000,1.28,1.1328126,1672444800,1703980800,1688083200,-145076000,-0.95,-0.91,129.835,-0.257,-0.6081081,0.14113986,NGM,EQUITY,ATAI,ATAI,ATAI Life Sciences N.V.,Atai Life Sciences N.V.,1624023000,America/New_York,EDT,8699f3bf-7398-34d0-b0ba-129948e2583d,finmb_710359021,-14400000,1.45,21.0,5.1,11.73,11.0,1.8,buy,9,227492000,1.37,-137632000,19005000,12.789,13.543,272000,8.813,0.002,-0.28601,-0.56173,233000,-56181624,-102275000,0.012,1.0,0.0,-506.8566,USD,
2,Wallstrasse 16,Berlin,10179,Germany,49 89 2153 9035,49 89 2153 9035 1,https://www.atai.life,Biotechnology,Biotechnology,Healthcare,Healthcare,"ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; GRX-917, a deuterated etifoxine for anxiety disorders; VLS-01 a N,N-Dimethyltryptamine for treatment resistant depression (TRD); DMX-1002, an oral formulation of ibogaine, a cholinergic, glutamatergic and monoaminergic receptor modulator that is a naturally occurring psychedelic product isolated from a West African shrub for the treatment of opioid use disorders (OUD); and EMP-01, an oral formulation of an MDMA derivative being developed for the treatment of post-traumatic stress disorder. The company's other clinical programs comprise PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; and KUR-101, a formulation of deuterated mitragynine for the treatment of OUD. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.",133,"{'maxAge': 1, 'name': 'Dr. Srinivas G. Rao M.D., Ph.D.', 'age': 53, 'title': 'Co-Founder & Chief Scientific Officer', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 834150, 'exercisedValue': 0, 'unexercisedValue': 457481}",1672444800,86400,4,1.45,1.47,1.44,1.485,1.45,1.47,1.44,1.485,0.0,0.826614,-1.5934066,637940,637940,934611,511050,511050,1.44,1.49,1400,2900,240714512,1.14,3.9,884.9798,1.7788,1.919475,0.0,0.0,USD,35315192,0.0,133273210,166010000,4124529,4089623,1690761600,1693440000,0.0248,0.09632,0.30329,7.1,0.0325,166010000,1.28,1.1328126,1672444800,1703980800,1688083200,-145076000,-0.95,-0.91,129.835,-0.257,-0.6081081,0.14113986,NGM,EQUITY,ATAI,ATAI,ATAI Life Sciences N.V.,Atai Life Sciences N.V.,1624023000,America/New_York,EDT,8699f3bf-7398-34d0-b0ba-129948e2583d,finmb_710359021,-14400000,1.45,21.0,5.1,11.73,11.0,1.8,buy,9,227492000,1.37,-137632000,19005000,12.789,13.543,272000,8.813,0.002,-0.28601,-0.56173,233000,-56181624,-102275000,0.012,1.0,0.0,-506.8566,USD,
3,Wallstrasse 16,Berlin,10179,Germany,49 89 2153 9035,49 89 2153 9035 1,https://www.atai.life,Biotechnology,Biotechnology,Healthcare,Healthcare,"ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; GRX-917, a deuterated etifoxine for anxiety disorders; VLS-01 a N,N-Dimethyltryptamine for treatment resistant depression (TRD); DMX-1002, an oral formulation of ibogaine, a cholinergic, glutamatergic and monoaminergic receptor modulator that is a naturally occurring psychedelic product isolated from a West African shrub for the treatment of opioid use disorders (OUD); and EMP-01, an oral formulation of an MDMA derivative being developed for the treatment of post-traumatic stress disorder. The company's other clinical programs comprise PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; and KUR-101, a formulation of deuterated mitragynine for the treatment of OUD. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.",133,"{'maxAge': 1, 'name': 'Mr. Stephen B. Bardin', 'age': 31, 'title': 'MD & CFO', 'yearBorn': 1991, 'fiscalYear': 2022, 'totalPay': 651322, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.45,1.47,1.44,1.485,1.45,1.47,1.44,1.485,0.0,0.826614,-1.5934066,637940,637940,934611,511050,511050,1.44,1.49,1400,2900,240714512,1.14,3.9,884.9798,1.7788,1.919475,0.0,0.0,USD,35315192,0.0,133273210,166010000,4124529,4089623,1690761600,1693440000,0.0248,0.09632,0.30329,7.1,0.0325,166010000,1.28,1.1328126,1672444800,1703980800,1688083200,-145076000,-0.95,-0.91,129.835,-0.257,-0.6081081,0.14113986,NGM,EQUITY,ATAI,ATAI,ATAI Life Sciences N.V.,Atai Life Sciences N.V.,1624023000,America/New_York,EDT,8699f3bf-7398-34d0-b0ba-129948e2583d,finmb_710359021,-14400000,1.45,21.0,5.1,11.73,11.0,1.8,buy,9,227492000,1.37,-137632000,19005000,12.789,13.543,272000,8.813,0.002,-0.28601,-0.56173,233000,-56181624,-102275000,0.012,1.0,0.0,-506.8566,USD,
4,Wallstrasse 16,Berlin,10179,Germany,49 89 2153 9035,49 89 2153 9035 1,https://www.atai.life,Biotechnology,Biotechnology,Healthcare,Healthcare,"ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; GRX-917, a deuterated etifoxine for anxiety disorders; VLS-01 a N,N-Dimethyltryptamine for treatment resistant depression (TRD); DMX-1002, an oral formulation of ibogaine, a cholinergic, glutamatergic and monoaminergic receptor modulator that is a naturally occurring psychedelic product isolated from a West African shrub for the treatment of opioid use disorders (OUD); and EMP-01, an oral formulation of an MDMA derivative being developed for the treatment of post-traumatic stress disorder. The company's other clinical programs comprise PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; and KUR-101, a formulation of deuterated mitragynine for the treatment of OUD. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.",133,"{'maxAge': 1, 'name': 'Mr. Frank  Stegert', 'age': 41, 'title': 'VP of Investment & Venture Management', 'yearBorn': 1981, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.45,1.47,1.44,1.485,1.45,1.47,1.44,1.485,0.0,0.826614,-1.5934066,637940,637940,934611,511050,511050,1.44,1.49,1400,2900,240714512,1.14,3.9,884.9798,1.7788,1.919475,0.0,0.0,USD,35315192,0.0,133273210,166010000,4124529,4089623,1690761600,1693440000,0.0248,0.09632,0.30329,7.1,0.0325,166010000,1.28,1.1328126,1672444800,1703980800,1688083200,-145076000,-0.95,-0.91,129.835,-0.257,-0.6081081,0.14113986,NGM,EQUITY,ATAI,ATAI,ATAI Life Sciences N.V.,Atai Life Sciences N.V.,1624023000,America/New_York,EDT,8699f3bf-7398-34d0-b0ba-129948e2583d,finmb_710359021,-14400000,1.45,21.0,5.1,11.73,11.0,1.8,buy,9,227492000,1.37,-137632000,19005000,12.789,13.543,272000,8.813,0.002,-0.28601,-0.56173,233000,-56181624,-102275000,0.012,1.0,0.0,-506.8566,USD,
5,Wallstrasse 16,Berlin,10179,Germany,49 89 2153 9035,49 89 2153 9035 1,https://www.atai.life,Biotechnology,Biotechnology,Healthcare,Healthcare,"ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; GRX-917, a deuterated etifoxine for anxiety disorders; VLS-01 a N,N-Dimethyltryptamine for treatment resistant depression (TRD); DMX-1002, an oral formulation of ibogaine, a cholinergic, glutamatergic and monoaminergic receptor modulator that is a naturally occurring psychedelic product isolated from a West African shrub for the treatment of opioid use disorders (OUD); and EMP-01, an oral formulation of an MDMA derivative being developed for the treatment of post-traumatic stress disorder. The company's other clinical programs comprise PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; and KUR-101, a formulation of deuterated mitragynine for the treatment of OUD. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.",133,"{'maxAge': 1, 'name': 'Ms. Anne  Johnson', 'title': 'Chief Accounting Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.45,1.47,1.44,1.485,1.45,1.47,1.44,1.485,0.0,0.826614,-1.5934066,637940,637940,934611,511050,511050,1.44,1.49,1400,2900,240714512,1.14,3.9,884.9798,1.7788,1.919475,0.0,0.0,USD,35315192,0.0,133273210,166010000,4124529,4089623,1690761600,1693440000,0.0248,0.09632,0.30329,7.1,0.0325,166010000,1.28,1.1328126,1672444800,1703980800,1688083200,-145076000,-0.95,-0.91,129.835,-0.257,-0.6081081,0.14113986,NGM,EQUITY,ATAI,ATAI,ATAI Life Sciences N.V.,Atai Life Sciences N.V.,1624023000,America/New_York,EDT,8699f3bf-7398-34d0-b0ba-129948e2583d,finmb_710359021,-14400000,1.45,21.0,5.1,11.73,11.0,1.8,buy,9,227492000,1.37,-137632000,19005000,12.789,13.543,272000,8.813,0.002,-0.28601,-0.56173,233000,-56181624,-102275000,0.012,1.0,0.0,-506.8566,USD,
6,Wallstrasse 16,Berlin,10179,Germany,49 89 2153 9035,49 89 2153 9035 1,https://www.atai.life,Biotechnology,Biotechnology,Healthcare,Healthcare,"ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; GRX-917, a deuterated etifoxine for anxiety disorders; VLS-01 a N,N-Dimethyltryptamine for treatment resistant depression (TRD); DMX-1002, an oral formulation of ibogaine, a cholinergic, glutamatergic and monoaminergic receptor modulator that is a naturally occurring psychedelic product isolated from a West African shrub for the treatment of opioid use disorders (OUD); and EMP-01, an oral formulation of an MDMA derivative being developed for the treatment of post-traumatic stress disorder. The company's other clinical programs comprise PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; and KUR-101, a formulation of deuterated mitragynine for the treatment of OUD. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.",133,"{'maxAge': 1, 'name': 'Mr. Ryan  Barrett', 'title': 'Gen. Counsel & Corp. Sec.', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.45,1.47,1.44,1.485,1.45,1.47,1.44,1.485,0.0,0.826614,-1.5934066,637940,637940,934611,511050,511050,1.44,1.49,1400,2900,240714512,1.14,3.9,884.9798,1.7788,1.919475,0.0,0.0,USD,35315192,0.0,133273210,166010000,4124529,4089623,1690761600,1693440000,0.0248,0.09632,0.30329,7.1,0.0325,166010000,1.28,1.1328126,1672444800,1703980800,1688083200,-145076000,-0.95,-0.91,129.835,-0.257,-0.6081081,0.14113986,NGM,EQUITY,ATAI,ATAI,ATAI Life Sciences N.V.,Atai Life Sciences N.V.,1624023000,America/New_York,EDT,8699f3bf-7398-34d0-b0ba-129948e2583d,finmb_710359021,-14400000,1.45,21.0,5.1,11.73,11.0,1.8,buy,9,227492000,1.37,-137632000,19005000,12.789,13.543,272000,8.813,0.002,-0.28601,-0.56173,233000,-56181624,-102275000,0.012,1.0,0.0,-506.8566,USD,
7,Wallstrasse 16,Berlin,10179,Germany,49 89 2153 9035,49 89 2153 9035 1,https://www.atai.life,Biotechnology,Biotechnology,Healthcare,Healthcare,"ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; GRX-917, a deuterated etifoxine for anxiety disorders; VLS-01 a N,N-Dimethyltryptamine for treatment resistant depression (TRD); DMX-1002, an oral formulation of ibogaine, a cholinergic, glutamatergic and monoaminergic receptor modulator that is a naturally occurring psychedelic product isolated from a West African shrub for the treatment of opioid use disorders (OUD); and EMP-01, an oral formulation of an MDMA derivative being developed for the treatment of post-traumatic stress disorder. The company's other clinical programs comprise PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; and KUR-101, a formulation of deuterated mitragynine for the treatment of OUD. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.",133,"{'maxAge': 1, 'name': 'Dr. Rolando  Gutierrez-Esteinou M.D.', 'age': 61, 'title': 'Chief Medical Officer', 'yearBorn': 1961, 'fiscalYear': 2021, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.45,1.47,1.44,1.485,1.45,1.47,1.44,1.485,0.0,0.826614,-1.5934066,637940,637940,934611,511050,511050,1.44,1.49,1400,2900,240714512,1.14,3.9,884.9798,1.7788,1.919475,0.0,0.0,USD,35315192,0.0,133273210,166010000,4124529,4089623,1690761600,1693440000,0.0248,0.09632,0.30329,7.1,0.0325,166010000,1.28,1.1328126,1672444800,1703980800,1688083200,-145076000,-0.95,-0.91,129.835,-0.257,-0.6081081,0.14113986,NGM,EQUITY,ATAI,ATAI,ATAI Life Sciences N.V.,Atai Life Sciences N.V.,1624023000,America/New_York,EDT,8699f3bf-7398-34d0-b0ba-129948e2583d,finmb_710359021,-14400000,1.45,21.0,5.1,11.73,11.0,1.8,buy,9,227492000,1.37,-137632000,19005000,12.789,13.543,272000,8.813,0.002,-0.28601,-0.56173,233000,-56181624,-102275000,0.012,1.0,0.0,-506.8566,USD,
8,Wallstrasse 16,Berlin,10179,Germany,49 89 2153 9035,49 89 2153 9035 1,https://www.atai.life,Biotechnology,Biotechnology,Healthcare,Healthcare,"ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; GRX-917, a deuterated etifoxine for anxiety disorders; VLS-01 a N,N-Dimethyltryptamine for treatment resistant depression (TRD); DMX-1002, an oral formulation of ibogaine, a cholinergic, glutamatergic and monoaminergic receptor modulator that is a naturally occurring psychedelic product isolated from a West African shrub for the treatment of opioid use disorders (OUD); and EMP-01, an oral formulation of an MDMA derivative being developed for the treatment of post-traumatic stress disorder. The company's other clinical programs comprise PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; and KUR-101, a formulation of deuterated mitragynine for the treatment of OUD. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.",133,"{'maxAge': 1, 'name': 'Dr. Sahil V. Kirpekar M.D.', 'age': 37, 'title': 'Chief Bus. Officer', 'yearBorn': 1985, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.45,1.47,1.44,1.485,1.45,1.47,1.44,1.485,0.0,0.826614,-1.5934066,637940,637940,934611,511050,511050,1.44,1.49,1400,2900,240714512,1.14,3.9,884.9798,1.7788,1.919475,0.0,0.0,USD,35315192,0.0,133273210,166010000,4124529,4089623,1690761600,1693440000,0.0248,0.09632,0.30329,7.1,0.0325,166010000,1.28,1.1328126,1672444800,1703980800,1688083200,-145076000,-0.95,-0.91,129.835,-0.257,-0.6081081,0.14113986,NGM,EQUITY,ATAI,ATAI,ATAI Life Sciences N.V.,Atai Life Sciences N.V.,1624023000,America/New_York,EDT,8699f3bf-7398-34d0-b0ba-129948e2583d,finmb_710359021,-14400000,1.45,21.0,5.1,11.73,11.0,1.8,buy,9,227492000,1.37,-137632000,19005000,12.789,13.543,272000,8.813,0.002,-0.28601,-0.56173,233000,-56181624,-102275000,0.012,1.0,0.0,-506.8566,USD,
